Cox2 oncolytic adenovirus

Cox2 oncolytic adenovirus is a tumor-selective replicating adenoviral vector engineered to target cancer cells that overexpress cyclooxygenase-2 (COX-2). The virus typically utilizes the COX-2 promoter to drive the expression of essential early viral genes (such as E1A), thereby restricting viral replication and subsequent oncolysis to COX-2-positive malignant cells while sparing healthy tissue. Developed by researchers at the University of Minnesota, this platform has been evaluated in various solid tumors, including pancreatic cancer and esophageal adenocarcinoma. It is often studied in combination with chemotherapeutic agents like 5-fluorouracil (5FU) or engineered to express therapeutic transgenes such as human interferon (hIFN) to enhance anti-tumor efficacy and stimulate a systemic immune response.

Other names

Cox2-selective oncolytic adenovirusCox-2-selective oncolytic adenovirusCox 2-selective oncolytic adenovirusCox2-driven oncolytic adenovirusCox-2-driven oncolytic adenovirusCox 2-driven oncolytic adenovirus